Ligand Pharma (LGND) Misses Q1 EPS by 21c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $285.60 -1.43%
EPS Growth %: -24.9%
Financial Fact:
Loss from operations: 5.47M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -24.9%
Financial Fact:
Loss from operations: 5.47M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q1 EPS of $1.63, $0.21 worse than the analyst estimate of $1.84. Revenue for the quarter came in at $51.72 million versus the consensus estimate of $59.07 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- Nomura/Instinet Upgrades MR DIY Group M Bhd (MRDIY:MK) to Buy
- Jefferies Downgrades Xior Student Housing NV (XIOR:BB) to Hold
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
